| Autor: |
Chung, Hyun, Hendrik-Tobias Arkenau, Jeeyun Lee, Rha, Sun, Do-Youn Oh, Wyrwicz, Lucjan, Yoon-Koo Kang, Keun-Wook Lee, Infante, Jeffrey, Lee, Sung, Kemeny, Margaret, Keilholz, Ulrich, Melichar, Bohuslav, Mita, Alain, Plummer, Ruth, Smith, Denis, Gelb, Arnold, Huiling Xiong, Hong, Janet, Chand, Vikram, Safran, Howard |
| Rok vydání: |
2019 |
| DOI: |
10.6084/m9.figshare.7672292 |
| Popis: |
Table S1. Eligibility criteria. Table S2. Response to avelumab in the 1 L-mn and 2 L subgroups. Table S3. Best response to avelumab compared with best response to prior anticancer therapy in the 1 L-mn subgroup. Table S4. Overall summary of safety. Figure S1. Time to and duration of response in responding patients. Figure S2. Best change in sum of target lesion diameters from baseline with avelumab in evaluable patients. Figure S3. Progression-free survival by PD-L1 expression status (≥1% tumor cell cutoff) in evaluable patients. Figure S4. Overall survival by PD-L1 expression status (≥1% tumor cell cutoff) in evaluable patients. (DOCX 794 kb) |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
